ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2026)
ARS Pharmaceuticals' (SPRY) quarterly EBITDA Margin came in at 268.24% in Q1 2026, up 15931.0% year-on-year from N/an in Q1 2025, and down 82.9% quarter-over-quarter from 146.66% in Q4 2025.
ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has disclosed EBITDA Margin across 5 years of filings, most recently posting 268.24% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 268.24%, up 15931.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 200.17% (down 18426.0% YoY), and the FY2025 annual result was 203.37%, down 21253.0% from the prior year.
- EBITDA Margin came in at 268.24% for Q1 2026 at ARS Pharmaceuticals, down from 146.66% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 57.54% in Q4 2024 to a low of 176180.0% in Q2 2023.
- The 5-year median for EBITDA Margin is 901.55% (2024), against an average of 20252.13%.
- Across the five-year window, EBITDA Margin tumbled 17479638 bps in 2023 and soared 17367260 bps in 2024, its largest moves.
- ARS Pharmaceuticals' EBITDA Margin stood at 3483.07% in 2022, then tumbled by 4958 bps to 176180.0% in 2023, then soared by 100 bps to 57.54% in 2024, then plunged by 355 bps to 146.66% in 2025, then plunged by 83 bps to 268.24% in 2026.
- The last three EBITDA Margin figures came in at 268.24% (Q1 2026), 146.66% (Q4 2025), and 157.26% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - | -268.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -268.24% |
| Dec 31, 2025 | -146.66% |
| Sep 30, 2025 | -157.26% |
| Jun 30, 2025 | -286.32% |
| Mar 31, 2025 | -427.54% |
| Dec 31, 2024 | 57.54% |
| Sep 30, 2024 | -901.55% |
| Jun 30, 2024 | -2,507.40% |
| Jun 30, 2023 | -176,180.00% |
| Mar 31, 2023 | -76,500.00% |
| Sep 30, 2022 | -3,483.07% |
| Jun 30, 2022 | -1,383.62% |
| Mar 31, 2022 | -1,093.51% |